Lyophilized Biologics and Vaccines: Modality-Based Approaches
Editat de Dushyant Varshney, Manmohan Singhen Limba Engleză Hardback – 21 mai 2015
Lyophilized Biologics and Vaccines: Modality-Based Approaches is composed of four sections with a total of 17 chapters. It serves as a reference to all critical assessments and steps from early pre-formulation stages to product launch:
- Provides recent understanding of heterogeneity of protein environment and selection of appropriate buffer for stabilization of lyophilized formulations
- Details the latest developments in instrumental analysis and controlled ice nucleation technology
- Explains in-depth lyophilized (or dehydrated) formulation strategies considering diverse modalities of biologics and vaccines, including plasmid DNA and lipid-based therapeutics
- Details an exhaustive update on quality-by-design and process analytical technology approaches, illustrated superbly by case studies and FDA perspective
- Provides the latest detailed account of alternate drying technologies including spray drying, bulk freeze-drying and crystallization, supported exceptionally by case studies
- Provides a step-by-step guide through critical considerations during process scale-up, technology transfer,packaging and drug delivery device selection, for a successful lyophilization process validation, regulatory submission and product launch
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 834.21 lei 43-57 zile | |
Springer – 9 oct 2016 | 834.21 lei 43-57 zile | |
Hardback (1) | 1151.26 lei 43-57 zile | |
Springer – 21 mai 2015 | 1151.26 lei 43-57 zile |
Preț: 1151.26 lei
Preț vechi: 1211.86 lei
-5% Nou
Puncte Express: 1727
Preț estimativ în valută:
220.39€ • 226.66$ • 182.84£
220.39€ • 226.66$ • 182.84£
Carte tipărită la comandă
Livrare economică 17 februarie-03 martie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781493923823
ISBN-10: 149392382X
Pagini: 518
Ilustrații: XI, 401 p. 99 illus., 68 illus. in color.
Dimensiuni: 155 x 235 x 27 mm
Greutate: 0.76 kg
Ediția:2015
Editura: Springer
Colecția Springer
Locul publicării:New York, NY, United States
ISBN-10: 149392382X
Pagini: 518
Ilustrații: XI, 401 p. 99 illus., 68 illus. in color.
Dimensiuni: 155 x 235 x 27 mm
Greutate: 0.76 kg
Ediția:2015
Editura: Springer
Colecția Springer
Locul publicării:New York, NY, United States
Public țintă
ResearchCuprins
Preface.- Part I – Lyophilization History and Fundamentals.- History of Lyophilization.- Heterogeneity of protein environments in frozen solutions and in the dried state.- Advance understanding of buffer behavior during lyophilization.- Advances in Instrumental Analysis Applied to the Development of Lyophilization Cycles.- New Developments in Controlled Nucleation: Commercializing VERISEQ® Nucleation technology.- Part II – Lyophilized Biologics and Vaccines – Modality Considerations.- Lyophilized Biologics.- Lyophilization of Therapeutic Proteins in Vials - Process Scale-up and Advances in Quality by Design.- Advances in Process Analytical Technology in Freeze Drying.- Process Scale-up and Optimization of Lyophilized Vaccine Products.- Stabilization of Plasmid DNA and Lipid-based Therapeutics as Dehydrated Formulations.- Part III – Advances in Alternate Drying.- Alternatives to Vial Lyophilization.- Spray Drying of Biopharmaceuticals.- Current Trends and Advances in Bulk Crystallization and Freeze Drying of Biopharmaceuticals.- Case Studies and Examples of Biopharmaceutical Modalities.- Processed by Bulk Crystallization or Bulk Freeze Drying.- Part IV– Regulatory, Packaging and Technology Transfer Considerations.- Lyophilization of Biologics - An FDA Perspective.- Recent Trends in Lyophilized Delivery Devices and Packaging.- Lyophilization Technology Transfer towards Product Launch.
Notă biografică
Dushyant B. Varshney, Ph. D., has made significant contributions in manufacturing science and technology, tech transfer, product and process development (including lyophilization), quality-by-design and process analytical technologies for biologics, vaccines and small molecules. Having earned his Ph.D. from the University of Iowa, Dr. Varshney has authored several peer-reviewed scientific publications, review articles, and book chapters, and has presented at several international conferences and chaired scientific workshops. He is currently a Director of Manufacturing Assessment, MS&T at Hospira, Inc. He has previously worked at Novartis, Bristol-Myers Squibb, Sanofi and Eli Lilly & Company.
Manmohan Singh, Ph.D., is a well-known expert in the area of vaccine formulations and adjuvant research, and has been working in vaccine R&D for the last 20 years. He has authored over 130 peer reviewed manuscripts, review articles, and book chapters, and has edited five books in this area. Dr. Singh is on the editorial board of 11 International Journals and has collaborated in organizing several international vaccine conferences. Currently, he is the Head of Global Drug Product Development at Novartis Vaccines and Diagnostics in Holly Springs, NC 27540.
Manmohan Singh, Ph.D., is a well-known expert in the area of vaccine formulations and adjuvant research, and has been working in vaccine R&D for the last 20 years. He has authored over 130 peer reviewed manuscripts, review articles, and book chapters, and has edited five books in this area. Dr. Singh is on the editorial board of 11 International Journals and has collaborated in organizing several international vaccine conferences. Currently, he is the Head of Global Drug Product Development at Novartis Vaccines and Diagnostics in Holly Springs, NC 27540.
Textul de pe ultima copertă
This book provides a detailed account of the most recent developments, challenges and solutions to seamlessly advance and launch lyophilized biologics or vaccine products, based on diverse modalities, ranging from antibodies (e.g., monoclonal, fusion), complex biologics (e.g., antibody drug conjugates, PEGylated proteins) and vaccines (e.g., recombinant protein based). The authors adeptly guide you through everything you need to know, from biophysical and chemical stability considerations of proteins, to critical assessment during process scale-up, technology transfer, packaging, alternate drying and device selection for a successful process validation, regulatory submission and launch of a stable, safe and effective product.
Lyophilized Biologics and Vaccines: Modality-Based Approaches serves as a reference to all critical assessments and steps from early pre-formulation stages to product launch:
Dushyant B. Varshney, Ph.D., has made significant contributions in manufacturing science and technology, due diligence, tech transfer, product and process development (including lyophilization), quality-by-design and process analytical technologies for biologics, vaccines and small molecules. He is currently a Director of Manufacturing Assessment, MS&T at Hospira Inc.
Manmohan Singh, Ph.D., is a well-known expert in the area of vaccine formulations and adjuvant research and has been working in vaccine R&D for the last 20 years. He is currently the Head of Global Drug Product Development at Novartis Vaccines and Diagnostics in Holly Springs, NC.
Lyophilized Biologics and Vaccines: Modality-Based Approaches serves as a reference to all critical assessments and steps from early pre-formulation stages to product launch:
- Provides recent understanding of heterogeneity of protein environment in frozen systems, buffer stabilization, instrumental analysis and controlled ice nucleation technology
- Details product development strategies based on diverse modalities of biologics and vaccines, including plasmid DNA and lipid-based therapeutics
- Recent updates on quality-by-design and process analytical technology approaches, illustrated by case studies and FDA perspective
- Provides the latest account of alternate drying technologies including spray drying and bulk freeze-drying
Dushyant B. Varshney, Ph.D., has made significant contributions in manufacturing science and technology, due diligence, tech transfer, product and process development (including lyophilization), quality-by-design and process analytical technologies for biologics, vaccines and small molecules. He is currently a Director of Manufacturing Assessment, MS&T at Hospira Inc.
Manmohan Singh, Ph.D., is a well-known expert in the area of vaccine formulations and adjuvant research and has been working in vaccine R&D for the last 20 years. He is currently the Head of Global Drug Product Development at Novartis Vaccines and Diagnostics in Holly Springs, NC.
Caracteristici
Explains in-depth lyophilized (or dehydrated) formulation strategies considering diverse modalities of biologics and vaccines, including plasmid DNA and lipid-based therapeutics Provides recent understanding of heterogeneity of protein environment and selection of appropriate buffer for stabilization of lyophilized formulations Details the latest developments in instrumental analysis and controlled ice nucleation technology Includes supplementary material: sn.pub/extras